Multislice Computed Tomography Angiography for Noninvasive Assessment of the 18-Month Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device

Because the first-generation Absorb (Abbott Vascular, Santa Clara, California) everolimus-eluting bioresorbable vascular scaffold (BVS) demonstrated late lumen loss thought to be caused by rapid changes in strut integrity (1), the second generation was designed for improved mechanical endurance and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2013-11, Vol.62 (19), p.1813-1814
Main Authors: Nieman, Koen, MD, PhD, Serruys, Patrick W., MD, PhD, Onuma, Yoshinobu, MD, van Geuns, Robert-Jan, MD, PhD, Garcia-Garcia, Hector M., MD, PhD, de Bruyne, Bernard, MD, PhD, Thuesen, Leif, MD, Smits, Pieter C., MD, PhD, Koolen, Jacques J., MD, PhD, McClean, Dougal, MD, Chevalier, Bernard, MD, Meredith, Ian, MD, Ormiston, John, MD, PhD
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Coronary vessels
Heart attacks
Internal Medicine
Stents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Because the first-generation Absorb (Abbott Vascular, Santa Clara, California) everolimus-eluting bioresorbable vascular scaffold (BVS) demonstrated late lumen loss thought to be caused by rapid changes in strut integrity (1), the second generation was designed for improved mechanical endurance and prolonged radial force. The ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions) trial (NCT00856856) is a nonrandomized multicenter, single-arm, efficacy-safety study.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2013.07.030